IDH1 and central nervous system cancer: Of the 56 cases of gliomas, IDH1 R132H mutant protein expression was seen in the neoplastic glial cells in 16 (28.6%) cases, while the majority (n = 40, 71.4%) were completely negative for the IDH1 R132H mutant protein (Figure 1).